[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yan Li\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100610852","phase-3-perirenal-adipose-tissue-modification-therapy-for-resistant-hypertension-100610852",false,"NCT07232966","Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension","The Efficacy and Safety of Perirenal Adipose Tissue Modification Therapy by Focused Power Ultrasound for Resistant Hypertension","PATH-RHT","Inclusion Criteria:\n\n1. Male or female participants aged 18-75 years old;\n2. 24h ambulatory systolic BP ≥130mmHg and \\\u003C150mmHg, and 24h ambulatory diastolic BP \\\u003C100mmHg after at least 4 weeks of combined treatment with 3 antihypertensive drugs (including a diuretic);\n3. The ultrasound measured inferior perirenal adipose tissue ≥8 cm3 (with the superior-inferior diameter, left-right diameter, and anterior-posterior diameter all needing to be ≥20 mm);\n4. Be willing to participate in the trial, and be able to visit doctors by himself or herself;\n5. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Secondary hypertension;\n2. Occurrence of myocardial infarction, malignant arrhythmia, severe renal failure, or stroke within 6 months;\n3. Ambulatory BP monitoring was invalid (\\\u003C70% valid readings, or \\\u003C20 daytime readings or \\\u003C7 nighttime readings);\n4. Alanine transaminase (ALT), aspartate transaminase (AST), or total bilirubin (TBL) above twice the normal range; eGFR (CKD-EPI) \\\u003C45mL\u002Fmin\u002F1.73m2;\n5. Type 1 diabetes mellitus or uncontrolled Type 2 diabetes mellitus (glycated hemoglobin ≥8.5%);\n6. Single functionally normal kidney or presence of renal malignant tumor;\n7. Bilateral skin diseases at renal region that are not suitable for the therapy;\n8. Women in pregnancy, lactating, or planning for pregnancy;\n9. Other concomitant diseases that are considered not suitable for participation in the trial;\n10. Patients have contraindications to angiotensin receptor-neprilysin inhibitor (ARNIs), thiazide-like diuretic drugs, or calcium channel blocker (CCBs);\n11. Non-compliant patients.","ALL","18 Years","75 Years",{"count":21,"type":22},220,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The goal of this clinical trial is to investigate if focused power ultrasound (FPU) targeted perirenal adipose tissue modification therapy would be effective and safe in treating resistant hypertension. The primary outcome of the study is the difference in the reduction of 24h mean systolic blood pressure between treatment and sham procedure groups 6 months after treatment. The secondary outcomes include the reduction of clinic blood pressure 1, 3, and 6 months after treatment, the reduction of 24h mean blood pressure 1, 3, and 6 months after treatment, and the drug burden of antihypertensive treatment. The safety evaluation includes the incidence of all-cause death, cardiovascular events (stroke and myocardial infarction), renal failure, and other adverse events.",[28],"Resistant Hypertension",[30,31],"perirenal adipose tissue","focused ultrasound","NOT_YET_RECRUITING","2025-11-14",{"date":35,"type":36},"2025-11-18","ACTUAL",{"date":38,"type":22},"2025-11-20",{"date":40,"type":22},"2029-06-30",{"name":42,"class":43},"Yan Li","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100446131","phase-4-morning-versus-bedtime-dosing-of-antihypertensive-medication-100446131","NCT05089448","Morning Versus Bedtime Dosing of Antihypertensive Medication","Morning Versus Bedtime Dosing of Antihypertensive Medication in Grade 1 Day-night Hypertension: a Multicenter Randomized Controlled Trial (Dosing-Time Trial)","Inclusion Criteria:\n\n1. Male or female patients aged 18-70 years old;\n2. Never treated for hypertension or stopped using antihypertensive drugs for at least 2 weeks;\n3. In the two screenings,the clinical systolic BP should be in the range of 140-159 mmHg, the diastolic BP \\\u003C 100 mmHg;\n4. The average 24-hour systolic BP ≥130mmHg, daytime systolic BP ≥ 135 mmHg, and nighttime systolic BP ≥ 120 mmHg;\n5. The average of bilateral brachial-ankle pulse wave velocity ≥14m\u002Fs;\n6. Be willing to participate in the trial, sign the informed consent form, and be able to visit doctors by himself or herself.\n\nExclusion Criteria:\n\n1. Secondary hypertension;\n2. Concomitant obstructive sleep apnea (STOP-BANG score ≥ 5), insomnia, Parkinson's syndrome, or nocturnal polyuria and other diseases that affect nighttime BP;\n3. Need to work at night;\n4. Ambulatory BP monitoring was invalid (\\\u003C70% valid readings, or \\\u003C20 daytime readings or \\\u003C7 nighttime readings);\n5. Concomitant diseases that need taking medications influencing BP;\n6. Coronary heart disease, myocardial infarction or stroke within recent 6 months;\n7. Atrial fibrillation or frequent arrhythmia;\n8. Abnormal liver function exemplified as an increased alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBL) over the double of the upper limit of normal range; abnormal renal function exemplified as a serum creatinine ≥176 µmol\u002FL; and plasma potassium ≥5.5 mmol\u002FL or ≤3.5mmol\u002FL;\n9. Pregnant or lactating women;\n10. Contraindications of angiotensin II receptor blocker or calcium channel blocker;\n11. Other concomitant diseases which are considered not suitable to participate in the trial, such as thyroid diseases, acute infectious diseases, chronic mental diseases, tumor, etc.","70 Years",{"count":54,"type":22},300,[56],"PHASE4","Previous studies have shown that elevated nighttime blood pressure (BP) was more closely associated with cardiovascular mortality and morbidity than daytime and clinic BPs. With increasingly advanced technology, not only 24-hour ambulatory but also home BP monitors can be used to evaluate nighttime BP. The validation study of the Omron HEM 9601T showed that the wrist-type home BP monitor could be a suitable and reliable tool for the diagnosis and management of nocturnal hypertension. However, up to now, there is no data on home nighttime BP in Chinese patients and it is unclear if different dosing time would reduce ambulatory and home nighttime BPs differently.\n\nThe investigators therefore designed a multicenter randomized clinical trial to compare between morning dosing and bedtime dosing of antihypertensive medications in the difference in nighttime, daytime and the 24-h BP reductions evaluated by both ambulatory and home BP monitoring, and in target organ protections.",[59,60,61],"Hypertension","Blood Pressure","Drug Use","RECRUITING","2025-01-03",{"date":65,"type":36},"2025-01-06",{"date":67,"type":36},"2021-01-28",{"date":69,"type":22},"2026-09-30",{"name":42,"class":43},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":44},"100327800","a-registry-study-on-the-action-of-controlling-ambulatory-blood-pressure-to-target-in-ten-thousand-patients-100327800","NCT03547856","A Registry Study on the \"Action of Controlling Ambulatory Blood Pressure to Target in Ten Thousand Patients\"","Inclusion Criteria:\n\n* Age 18-80 years old\n* Clinical diagnosed hypertension with the use of antihypertensive drugs\n* A 24-hour ambulatory blood pressure monitoring was performed with validated equipment.\n* Willing to provide information about disease history and blood biochemical test data within 6 months.\n* Sign the informed consent\n\nExclusion Criteria:\n\n* Without antihypertensive drug use\n* Hospitalized hypertension patients\n* Non-compliant patient","80 Years",{"count":79,"type":22},10000,"OBSERVATIONAL","24 hour ambulatory blood pressure (ABP) monitoring should be the first choice for diagnosis and treatment of hypertension according to European Societyof Hypertension (ESH) and the European Society of Cardiology (ESC) guideline on ambulatory blood pressure monitoring. Finally, we should promote the clinical application of 24 hour ambulatory blood pressure monitoring to greatly improve the management level of hypertension in China and effectively reduce the risk caused by hypertension in the population.\n\nInformation of hypertensive patients with ambulatory blood pressure monitoring was prospectively registered nationwide,and then to investigate whether there was difference in cardiovascular prognosis according to the control of ABP.",[59,60,83],"Cardiovascular Diseases",{"date":65,"type":36},{"date":86,"type":36},"2018-07-18",{"date":88,"type":22},"2026-12-30",{"name":42,"class":43},""]